3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:百万円)

 

前連結会計年度

(2025年3月31日)

当連結会計年度

(2026年3月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

10,603

10,126

売掛金

15,184

16,022

有価証券

555

893

商品及び製品

15,041

14,743

仕掛品

544

416

原材料及び貯蔵品

11,032

14,022

その他

5,423

5,265

貸倒引当金

94

67

流動資産合計

58,290

61,424

固定資産

 

 

有形固定資産

 

 

建物及び構築物

11,708

12,654

減価償却累計額

6,610

6,978

建物及び構築物(純額)

5,097

5,676

機械装置及び運搬具

17,168

18,040

減価償却累計額

15,047

15,612

機械装置及び運搬具(純額)

2,121

2,428

土地

4,255

4,186

建設仮勘定

6,508

6,078

その他

3,941

4,542

減価償却累計額

3,258

3,667

その他(純額)

683

874

有形固定資産合計

18,667

19,244

無形固定資産

 

 

のれん

2,611

2,354

その他

7,602

6,514

無形固定資産合計

10,213

8,869

投資その他の資産

 

 

投資有価証券

12,666

17,299

繰延税金資産

2,312

2,254

退職給付に係る資産

111

その他

2,162

2,827

貸倒引当金

17

17

投資その他の資産合計

17,123

22,474

固定資産合計

46,004

50,588

資産合計

104,295

112,012

 

 

 

 

(単位:百万円)

 

前連結会計年度

(2025年3月31日)

当連結会計年度

(2026年3月31日)

負債の部

 

 

流動負債

 

 

買掛金

6,411

5,288

電子記録債務

2,735

2,270

短期借入金

2,521

1,707

1年内返済予定の長期借入金

1,940

1,562

未払金

6,194

6,446

未払法人税等

173

1,574

賞与引当金

1,210

1,250

役員賞与引当金

73

66

その他

1,617

2,124

流動負債合計

22,879

22,291

固定負債

 

 

長期借入金

6,441

8,165

退職給付に係る負債

206

23

その他

2,952

5,080

固定負債合計

9,601

13,268

負債合計

32,480

35,559

純資産の部

 

 

株主資本

 

 

資本金

1,197

1,197

資本剰余金

31

利益剰余金

59,545

63,352

自己株式

704

658

株主資本合計

60,039

63,923

その他の包括利益累計額

 

 

その他有価証券評価差額金

4,853

5,646

為替換算調整勘定

292

退職給付に係る調整累計額

417

716

その他の包括利益累計額合計

5,271

6,070

非支配株主持分

6,504

6,459

純資産合計

71,814

76,452

負債純資産合計

104,295

112,012

 

E3579148860あすか製薬ホールディングス株式会社ASKA Pharmaceutical Holdings Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse488602024-04-012025-03-31jppfs_cor:NonControllingInterestsMember488602024-04-012025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602024-03-31jppfs_cor:NonControllingInterestsMember488602025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-04-012026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember488602025-04-012026-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602026-03-31jppfs_cor:ShareholdersEquityMember488602026-03-31jppfs_cor:TreasuryStockMember488602026-03-31jppfs_cor:RetainedEarningsMember488602026-03-31jppfs_cor:CapitalSurplusMember488602026-03-31jppfs_cor:CapitalStockMember488602024-03-31jppfs_cor:ShareholdersEquityMember488602024-03-31jppfs_cor:CapitalStockMember488602024-03-31jppfs_cor:CapitalSurplusMember488602024-03-31jppfs_cor:RetainedEarningsMember488602024-03-31jppfs_cor:TreasuryStockMember488602024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602024-04-012025-03-31jppfs_cor:ShareholdersEquityMember488602024-04-012025-03-31jppfs_cor:CapitalStockMember488602024-04-012025-03-31jppfs_cor:CapitalSurplusMember488602024-04-012025-03-31jppfs_cor:RetainedEarningsMember488602024-04-012025-03-31jppfs_cor:TreasuryStockMember488602024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602026-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602026-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602026-03-31jpcrp_cor:ReconcilingItemsMember488602025-04-012026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602025-04-012026-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602025-04-012026-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember488602025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-03-31jpcrp_cor:ReconcilingItemsMember488602024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602024-04-012025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602024-04-012025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-04-012026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember488602026-03-31jppfs_cor:NonControllingInterestsMember488602025-04-012026-03-31jppfs_cor:NonControllingInterestsMember488602025-03-31jppfs_cor:NonControllingInterestsMember488602026-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602025-04-012026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-04-012026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602025-04-012026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602025-04-012026-03-31jppfs_cor:ShareholdersEquityMember488602025-04-012026-03-31jppfs_cor:TreasuryStockMember488602025-04-012026-03-31jppfs_cor:RetainedEarningsMember488602025-04-012026-03-31jppfs_cor:CapitalSurplusMember488602025-04-012026-03-31jppfs_cor:CapitalStockMember488602025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602025-03-31jppfs_cor:ShareholdersEquityMember488602025-03-31jppfs_cor:TreasuryStockMember488602025-03-31jppfs_cor:RetainedEarningsMember488602025-03-31jppfs_cor:CapitalSurplusMember488602025-03-31jppfs_cor:CapitalStockMember488602025-04-012026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602026-05-11488602026-03-31488602025-04-012026-03-31488602025-03-31488602024-04-012025-03-31488602024-03-31xbrli:pureiso4217:JPY